f825534d-5882-4efe-a32e-af56741854f6
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 76
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- HEDGEHOG_SIGNALING+0.570
- ANGIOGENESIS+0.430
- UV_RESPONSE_DN+0.420
- APICAL_SURFACE+0.390
- MYOGENESIS+0.390
- TGF_BETA_SIGNALING+0.320
- APICAL_JUNCTION+0.290
- WNT_BETA_CATENIN_SIGNALING+0.240
- HYPOXIA+0.220
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.620
- INTERFERON_ALPHA_RESPONSE-0.510
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.510
- INTERFERON_GAMMA_RESPONSE-0.420
- FATTY_ACID_METABOLISM-0.400
- MYC_TARGETS_V1-0.350
- XENOBIOTIC_METABOLISM-0.350
- P53_PATHWAY-0.340
- ADIPOGENESIS-0.320
- MYC_TARGETS_V2-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613779 | — | D | 0.871 |
| 2 | 9ca22f6c-326b-4844-8e7d-fb076c7e1067 | — | — | 0.867 |
| 3 | 4b3022ba-0232-493c-b3fc-2447e8cf7113 | — | — | 0.835 |
| 4 | MBCProject_0044_T1_RNA | — | A | 0.833 |
| 5 | SRR8613703 | — | D | 0.827 |
| 6 | TCGA-AO-A12C-01A-11R-A10J-07 | — | A | 0.822 |
| 7 | f65f4ed5-9726-4eff-8638-63752686d2c9 | — | — | 0.821 |
| 8 | ee3e7969-ff2a-4b27-8f15-6cb46eed7c61 | — | — | 0.817 |
| 9 | TCGA-DK-A3IQ-01A-31R-A32Y-07 | — | — | 0.815 |
| 10 | TCGA-56-8626-01A-11R-2403-07 | — | cohortSQ1 | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.570 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.420 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.390 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.390 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.090 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.030 | Idelalisib | — uncovered |